AMPH · XBRL financial data

Amphastar Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AMPH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	350	438	499	644	732	720
Cost of revenue	207	238	250	293	358	364
Gross profit	143	200	249	351	374	356
Research and development	67	61	75	74	74	86
General and administrative	50	51	45	52	57	86
Total operating expenses	132	130	141	154	168	216
Operating income (loss)	11	70	107	197	205	140
Interest income	1	1	1	5	11	9
Interest expense	0	1	2	27	30	25
Other income (expense)	(7)	15	9	(4)	4	0
Income tax expense (benefit)	4	21	23	32	30	26
Net income (loss)	1	62	91	138	160	98
Earnings per share, basic USD per share	0.03	1.30	1.88	2.85	3.29	2.10
Earnings per share, diluted USD per share	0.03	1.25	1.74	2.60	3.06	2.03
Weighted average shares, basic millions of shares	47	48	49	48	48	47
Weighted average shares, diluted millions of shares	49	50	52	53	52	48

Fiscal years (AMPH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	93	126	156	144	152	170
Short-term investments	13	10	20	113	70	113
Accounts receivable	66	79	89	115	136	144
Inventory	97	93	104	106	154	177
Prepaid and other current assets	7	7	8	9	18	13
Total current assets	280	318	378	490	534	636
Property and equipment, net	260	244	238	283	297	311
Right-of-use asset	20	27	26	32	47	43
Goodwill	4	3	3	3	3	3
Total assets	631	672	742	1,513	1,577	1,629
Accounts payable	24	22	21	25	31	33
Accrued liabilities	71	67	64	68	127	116
Total current liabilities	112	104	95	225	174	158
Long-term debt	46	78	77	603	614	620
Lease liability, non-current	17	25	24	30	42	38
Total liabilities	183	226	213	873	845	840
Retained earnings	118	180	272	409	569	667
Total stockholders' equity	402	446	—	—	—	—
Total liabilities and equity	631	672	742	1,513	1,577	1,629
Common shares outstanding (cover page) millions of shares	47	48	48	48	48	45

Fiscal years (AMPH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	1	62	91	138	160	98
Stock-based compensation	20	19	18	20	24	27
Depreciation and amortization	9	10	13	26	—	—
Net cash from operating activities	57	98	89	184	213	156
Purchases of property and equipment	34	27	24	38	41	35
Net cash from investing activities	(36)	(29)	(33)	(649)	(125)	(70)
Share repurchases	24	29	40	58	85	76
Proceeds from long-term debt	6	70	—	845	—	—
Repayments of long-term debt	8	37	2	319	8	0
Net cash from financing activities	(2)	(37)	(26)	454	(81)	(67)
Net change in cash	19	32	30	(12)	7	19

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Amphastar Pharmaceuticals	224	184	51*	42.5M	—	Q2 FY26 10-QJun 30, 2026
Anaptysbio	134	27*	(27)*	29.9M	6.2 quarters	Q4 FY26 10-KTJun 30, 2026
Stoke Therapeutics	107	11	(63)*	65.4M	5.2 quarters	Q3 FY26 10-QSep 30, 2026
Trevi Therapeutics	54	not reported	(17)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
ImmunityBio	76	51	(66)*	1.1B	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Anavex Life Sciences	118	not reported	(9.1)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026
Evolus	42	78	(1.9)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
Xencor	60	117	2.6*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Immunome	218	0	(62)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.